What was studied?
Twelve participants with Barth syndrome entered a double-blind, placebo-controlled crossover study. Walking distance and a symptom scale were primary endpoints. A subset continued into an open-label extension after the randomized comparison.
What did the researchers report?
Neither primary endpoint was met during the randomized portion. Improvements in walking distance and symptom scores were reported during the later open-label period, which had fewer participants and no concurrent blinded placebo comparison.
What are the limits?
Findings from these two phases should not be combined as if they carried the same causal certainty. Rare-disease sample size, crossover design and attrition matter. The study concerns a defined pharmaceutical product and disease population, not general energy-enhancement claims for research materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.